Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.83 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.83 |
| ▸ | PGR | P06401 | 3/20 | 0.83 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.83 |
| ▸ | SHBG | P04278 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL1807734 | 1.00 | HIF1A (0.83) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| Hydrocortisone SCHEMBL4697 | 0.98 | HIF1A (0.86) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| Hydrocortisone SCHEMBL28908729 | 0.98 | HIF1A (0.86) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| Hydrocortisone SCHEMBL27961626 | 0.97 | HIF1A (0.85) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| Hydrocortisone SCHEMBL27804799 | 0.97 | HIF1A (0.83) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| Hydrocortisone SCHEMBL28435897 | 0.96 | HIF1A (0.82) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| Hydrocortisone SCHEMBL29263567 | 0.96 | HIF1A (0.82) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| Hydrocortisone SCHEMBL4278629 | 0.96 | HIF1A (0.91) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| Hydrocortisone SCHEMBL180227 | 0.96 | HIF1A (0.91) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| Hydrocortisone SCHEMBL26659908 | 0.95 | HIF1A (0.89) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744657-A1 | THERAPEUTIC AGENT FOR HUMAN GRAFT VERSUS HOST DISEASE AND COMBINATION THEREOF | National University Corporation Okayama University (JP) | 2026-05-20 | — | — | EP | claimed |
| WO-2023160631-A1 | NANO PREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中南大学湘雅医院 | 2023-08-31 | — | — | WO | claimed |
| CN-116077465-A | Nanometer preparation for joint pain relief, and preparation method and application thereof | 中南大学湘雅医院 | 2023-05-09 | — | — | CN | claimed |
| US-11376262-B2 | Method of treating an inflammatory or infectious disease | ACTIVUS PHARMA CO., LTD. (JP) | 2022-07-05 | — | — | US | claimed |
| CN-111529684-A | Use of oral sustained release compositions containing cyclosporin | 卓越治疗有限公司 | 2020-08-14 | — | — | CN | claimed |
| US-20200129526-A1 | METHOD OF TREATING AN INFLAMMATORY OR INFECTIOUS DISEASE | FORMOSA PHARMACEUTICALS, INC. (TW) | 2020-04-30 | — | — | US | claimed |
| CN-110945016-A | Peptide compounds, conjugate compounds and uses thereof for the treatment of inflammatory diseases | 特拉斯福特普拉斯公司 | 2020-03-31 | — | — | CN | claimed |
| US-10588913-B2 | Aqueous suspension agent containing glucocorticosteroid nanoparticles | ACTIVUS PHARMA CO., LTD. (JP) | 2020-03-17 | — | — | US | claimed |
| US-20180117064-A1 | AQUEOUS SUSPENSION AGENT CONTAINING GLUCOCORTICOSTEROID NANOPARTICLES | FORMOSA PHARMACEUTICALS, INC. (TW) | 2018-05-03 | — | — | US | claimed |
| EP-3295943-A1 | AQUEOUS SUSPENSION AGENT COMPRISING GLUCOCORTICOSTEROID NANOPARTICLES | Activus Pharma Co., Ltd. (JP) | 2018-03-21 | — | — | EP | claimed |
| EP-2050439-B1 | PROCESS FOR PRODUCTION OF SPHERICAL GRANULE CONTAINING SLIGHTLY WATER-SOLUBLE SUBSTANCE | ASAHI CHEMICAL IND (JP) | 2016-11-23 | — | — | EP | claimed |
| US-9095512-B2 | Method for producing spherical base granules comprising hardly water-soluble drug | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-08-04 | — | — | US | claimed |
| US-20090012051-A1 | EXTERNAL PREPARATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-01-08 | — | — | US | claimed |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-12-13 | — | — | US | claimed |
| EP-1810692-A1 | REMEDIES/PREVENTIVES FOR CHRONIC SKIN DISEASE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-25 | — | — | EP | claimed |
| WO-1997027862-A1 | SUPPLEMENTATION OF GLUCOCORTICOIDS | BELLARA MEDICAL PRODUCTS LIMITED (AU) | 1997-08-07 | — | — | WO | claimed |
| US-4794107-A | HYDROCORTISONE BUTYRATE PROPIONATE, PROPYLENE GLYCOL, SURFACTANTS, PARAFIN HYDROCARBONS; ANTIINFLAMMATORY AGENTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-27 | — | — | US | claimed |
| US-4794106-A | HYDROCORTISONE BUTYRATE PROPIONATE, HIGHER PARAFFINIC HYDROCARBON, SURFACTANT | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-27 | — | — | US | claimed |
| JP-61167614-A | — | — | None | — | — | JP | disclosed |
| JP-S59137408-A | OINTMENT | TAISHO PHARMACEUT CO LTD | 1984-08-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012051-A1 | EXTERNAL PREPARATION | CYP4A11, CYP46A1, CYP11B2 | NR3C1 556/4885HIF1A 1229/4885NR3C2 55/4885 |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | PDE4A, PDE3B, PDE2A | NR3C1 62/4885HIF1A 2269/4885NR3C2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.